BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27316584)

  • 1. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori.
    Shinozaki S; Nomoto H; Kondo Y; Sakamoto H; Hayashi Y; Yamamoto H; Lefor AK; Osawa H
    Kaohsiung J Med Sci; 2016 May; 32(5):255-60. PubMed ID: 27316584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
    Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
    Takara Y; Endo H; Nakano R; Kawachi K; Hidaka H; Matsunaga T; Tsuruoka N; Sakata Y; Shimoda R; Hara M; Fujimoto K
    Digestion; 2019; 99(2):172-178. PubMed ID: 30179876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
    Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
    Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
    Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
    Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2018 Aug; 34(8):456-460. PubMed ID: 30041763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C; Buranathawornsom A
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S; Nishikawa J; Sakaida I
    Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 16. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
    Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
    Liu MK; Wu IC; Lu CY; Kuo CH; Yu FJ; Liu CJ; Hsu PI; Hsu WH; Su YC; Chen A; Wu DC; Kuo FC; Chen JJ
    Kaohsiung J Med Sci; 2013 Jul; 29(7):379-84. PubMed ID: 23768702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Jung YS; Kim EH; Park CH
    Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
    Wu IC; Wu DC; Hsu PI; Lu CY; Yu FJ; Wang TE; Chang WH; Chen JJ; Kuo FC; Wu JY; Wang WM; Bair MJ
    Helicobacter; 2007 Dec; 12(6):633-7. PubMed ID: 18001406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.